When United States. Food and Drug Administration approve two gene therapies for sickle cell disease?

  • A. 8 December 2023
  • B. 7 December 2023
  • C. 11 December 2023
  • D. 12 December 2023

Correct Answer: A. 8 December 2023

The U.S. Food and Drug Administration (FDA) on 8 December 2023 approve two gene therapies for sickle cell disease, making one of them the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology. Casgevy, develop by partners Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN), and bluebird bio’s (BLUE.O) Lyfgenia were approved for people aged 12 years and older.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *